Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689–701.

Article  PubMed  Google Scholar 

Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21.

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–86.

Article  PubMed  Google Scholar 

Janmohamed M, Hakeem H, Ooi S, et al. Treatment outcomes of newly diagnosed epilepsy: a systematic review and meta-analysis. CNS Drugs. 2023;37(1):13–30.

Article  PubMed  Google Scholar 

Angelini Pharma S.p.A. Ontozry (cenobamate): EU summary of product characteristics 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry. Accessed 9 Jan 2025.

Hoy SM. Cenobamate in focal seizures: a profile of its use. Drugs Ther Perspect. 2020;36(8):327–34.

Article  Google Scholar 

Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.

Article  CAS  PubMed  Google Scholar 

Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Ontozry: EU assessment report. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry. Accessed 9 Jan 2025.

Klein P, Aboumatar S, Brandt C, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099–108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperling MR, Abou-Khalil B, Aboumatar S, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenfeld WE, Ferrari L, Kamin M. Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;183: 106940.

Article  CAS  PubMed  Google Scholar 

Aboumatar S, Biton V, Wechsler R, et al. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. Epilepsy Res. 2022;186: 107014.

Article  CAS  PubMed  Google Scholar 

Abou-Khalil B, Aboumatar S, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184: 106952.

Article  CAS  PubMed  Google Scholar 

Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brandt C, Sánchez-Álvarez JC, Steinhoff BJ, et al. Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86–93.

Article  PubMed  Google Scholar 

Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.

Article  CAS  PubMed  Google Scholar 

Serratosa J, Majkowska-Zwolińska B, Alvarez-Baron E, et al. Efficacy of adjunctive cenobamate for patients with different epilepsy aetiologies: results of an open-label study [abstract no. EPR-186]. Eur J Neurol. 2024;31(Suppl 1):e16338.

Nisman A, Rosenfeld W, Ferrari L. Long-term efficacy of cenobamate by focal seizure subtype: post-hoc analysis of an open-label extension study [abstract no. 1.31]. In: American Epilepsy Society Annual Meeting. 2023.

Brandt C, Fabó D, Milovanovic M, et al. Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study [abstract no. 1071]. Epilepsia. 2023;64(Suppl 2):58.

Sander JW, Rosenfeld WE, Halford JJ, et al. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139–49.

Article  CAS  PubMed  Google Scholar 

Novitskaya Y, Schütz E, Metternich B, et al. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2023;65(3):630–40.

Article  Google Scholar 

Lattanzi S, Ranzato F, Di Bonaventura C, et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: evidence from the first interim analysis of the BLESS study. Neurol Ther. 2024;13(4):1203–17.

Article  PubMed  PubMed Central  Google Scholar 

Winter Y, Abou Dargham R, Patino Tobon S, et al. Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study. CNS Drugs. 2024;38(9):733–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steinhoff BJ, Georgiou D, Intravooth T. The cenobamate KORK study: a prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam. Epilepsia Open. 2024;9(4):1502–14.

Article  PubMed  PubMed Central  Google Scholar 

Roberti R, Assenza G, Bisulli F, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia. 2024;65(10):2909–22.

Article  CAS  PubMed  Google Scholar 

Saouda C, Nofal O, Makke Y, et al. Effectiveness and tolerability of cenobamate: a single center experience. Epilepsy Res. 2025;209: 107498.

Article  CAS  PubMed  Google Scholar 

Peña-Ceballos J, Moloney PB, Munteanu T, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a “real-world” retrospective study. Epilepsia. 2023;64(5):1225–35.

Article  PubMed  Google Scholar 

Pietrafusa N, Falcicchio G, Russo E, et al. Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence? Front Pharmacol. 2023;14:1239152.

Villanueva V, Santos-Carrasco D, Cabezudo-García P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open. 2023;8(3):918–29.

Article  PubMed  PubMed Central  Google Scholar 

Beltrán-Corbellini Á, Romeral-Jiménez M, Mayo P, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71–7.

Article  PubMed  Google Scholar 

Lauxmann S, Heuer D, Heckelmann J, et al. Cenobamate: real-world data from a retrospective multicenter study. J Neurol. 2024;271(10):6596–604.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loushy I, Goldstein L, Devlin K, et al. Real-world use of cenobamate in adults: efficacy and predictors of treatment response. Epilepsia. 2025. https://doi.org/10.1111/epi.18297.

Article  PubMed  Google Scholar 

Roberti R, Di Gennaro G, Cianci V, et al. Exploring the effectiveness of adjunctive cenobamate in focal epilepsy: a time-based analysis. CNS Drugs. 2025.